Yet another biosimilar Herceptin set to come to European markets
As Swiss pharma giant Roche (ROG: SIX) starts facing up to biosimilars competition for some of its mega-selling biological drugs, yet another copy version has emerged.
Singapore-based Prestige BioPharma and privately-held US generics drugmaker Alvogen have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s trastuzumab biosimilar (HD201; Hervelous) in Central and Eastern Europe.
Hervelous is a monoclonal antibody (MAb) biosimilar to Roche’s Herceptin (trastuzumab), which is used to treat patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, and generated sales last year of $7.4 billion. Hervelous is in Phase III clinical development for filing with the European Medicines Agency and the US Food and Drug Administration in 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze